The 4th CRISPR MEDiCiNE Conference (CRISPRMED27) | Hybrid | Copenhagen, Denmark | April 19–22, 2027

**official website is live**

CRISPRMED27 brings together the global CRISPR and gene editing ecosystem for four days of scientific exchange, translational innovation, regulatory dialogue, patient perspectives, and industry collaboration in Copenhagen, Denmark, April 19-22, 2027.

As a fully hybrid event, the 4th edition of the CRISPR Medicine Conference is expected to welcome more than 1,000 onsite and online participants, including pioneering researchers, biotech and pharma leaders, clinicians, investors, patient advocates, regulators, technology providers, and patients and families helping shape the future of genomic medicine.

Attendees will gain access to a highly curated scientific programme featuring cutting-edge research, clinical and translational advances, regulatory perspectives, patient voices, hands-on workshops, satellite meetings, and emerging commercial opportunities across the CRISPR and gene editing landscape.

CRISPRMED27 uniquely connects science, medicine, industry, regulation, infrastructures and patient communities to accelerate the future of genomic medicine for rare diseases and complex cancers.

More details on speakers, committees, programme details, workshops, satellite meetings, and participation opportunities will be announced in the coming weeks (official website will be live June 26th).

Sign up to the CRISPRMED27 Newsletter

---------------

The CMN Global Clinical Trials Database 2.0 in now live...

Scientific Conference, April 20-22, 2027

Speakers (early confirmed):

Danny Cohn, Associate Professor (MD PhD), Amsterdam UMC, Department of Vascular Medicine, University of Amsterdam, Amsterdam, Netherlands (KEYNOTE SPEAKER)

• Alessia Cavazza, Ass. Prof. and Group Leader, Zayed Centre for Research into Rare Diseases in Children, UCL Great Ormond Street Institute of Child Health, University College London, UK, and Università degli Studi di Modena e Reggio Emilia, Italy.
• André Cohnen, VP, Head of Genomic Medicine at Bayer Pharmaceuticals, Germany.
• Anastasia Conti, Project Leader, San Raffaele Telethon Institute for Gene Therapy (SR-TIGET), Italy.
• Brad Ringeisen, Executive Director, Innovative Genomics Institute, University of California, Berkeley, United States.
• Cecilia Jimenez-Mallebrera, PhD and Research Director, Institut de Recerca Sant Joan de Déu, Hospital Sant Joan de Déu Barcelona and CIBERER, Spain.
• Daniël Warmerdam, Assistant Professor of Molecular Therapy Development, Emma Center for Personalized Medicine, Department of Human Genetics, Amsterdam UMC, Netherlands.
• Francisco J. Sánchez-Rivera, Eisen & Chang Career Development Assistant Professor of Biology, Koch Institute, Massachusetts Institute of Technology, United States.
• Jakob Nilsson, Professor and Group Leader, Danish Cancer Institute, Denmark.
• Julian Grünewald, Assistant Professor of Gene Editing, Technical University of Munich, Germany.
• Marcello Maresca, Senior Director Genome Engineering, RNA, Cell and Gene Therapy (RCGT), Discovery Sciences-BioPharmaceuticals R&D, AstraZeneca, Sweden.
• Marianne Carlon, Ass. Prof. at the Laboratory of Respiratory Diseases and Thoracic Surgery (BREATHE) and the Center for Molecular Medicine of the KU Leuven Faculty of Medicine, Belgium.
• Mario Amendola, PhD, Group Leader, Genethon, France.
• Michela Milani, PhD, Project Leader, San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), Italy.
• Michael Ott, Prof. Dr. Med., Hannover Medical School, Hannover, Germany.
• Özcan Met, PhD, Ass. Prof. and Head of Cell Therapy Unit and DTU HealthTech, CCIT-DK / DTU, Denmark.
• Silvana Libertini, PhD, Associate Director in Preclinical Safety at Novartis, Switzerland.
• Songyuan Li, PhD, Head of Genome Editing at AccurEdit Therapeutics, China.
• Stephan Kadauke, Associate Professor of Clinical Pathology and Lab Medicine, Children's Hospital of Philadelphia, United States.
• Toni Cathomen, PhD, Professor of Cell and Gene Therapy Director, ITG MEDICAL CENTER, Freiburg, Germany.
• ...

Check out the full official programme here...

Satellite Meetings, April 19, 2027

• EU Regulatory Requirements (CMC, pre-clinical, clinical)
• EU CRISPR Centers & Facilities Forum
• Access, IP Landscape & Freedom to Operate (FTO) in Europe and the US
• Special Global: CRISPR Medicine in Saudi Arabia: Clinical Translation, Collaboration, and Opportunities Ahead
  • Chairs: Dr. Mohammed Aljumah, ITKAN &, BIORIYAD CEO (Chair), Kingdom of Saudi Arabia, Dr. Mohamed Boudjelal, KAIMRC (Chair), Kingdom of Saudi Arabia

  • Speakers:

    • Dr. Mo Li, Principal Investigator, Stem Cell & Regeneration Lab, KAUST, Kingdom of Saudi Arabia

    • Dr. Mana Al Shehari (SFDA), Kingdom of Saudi Arabia

    • Dr. Majed Al Jeraisy (SNIH), Kingdom of Saudi Arabia

    • Dr. Khalid bin Adnan Al-Buraikan,Deputy Minister of Health for Investment, Kingdom of Saudi Arabia

    • Dr. Ahmed Alfares, King Faisal Specialist Hospital & Research Centre, Kingdom of Saudi Arabia

    • Prof. Imed Gallouzi, Chair of KAUST Center of Excellence for Smart-Health, Kingdom of Saudi Arabia

    • Prof. Majid Alfadhel, NGHA, KAIMRC, Kingdom of Saudi Arabia

• Special Global: CRISPR Medicine Landscape and Challenges in Africa